Transfusion of partially HLA-matched irradiated allogeneic blood mononuclear cells for advanced renal-tell carcinoma
- VernacularTitle:输注经照射的HLA部分相合的异基因单个核细胞治疗晚期肾细胞癌
- Author:
Nanfeng FAN
;
Yunbin YE
;
Rongbo LIN
;
Zengqing GUO
;
Zhifeng ZHOU
;
Xiaojie WANG
;
Mingshui CHEN
;
Shuping CHEN
;
Jieyu LI
;
Qiang CHEN
- Publication Type:Journal Article
- Keywords:
renal-cell carcinoma;
graft-versus-host disease;
partially HLA-matched;
immunotherapy
- From:
China Oncology
2009;19(10):766-769
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose: Renal-cell carcinoma (RCC) is susceptible to immune therapy including the use of the nonmyeloablative allogeneic transplantation(NAT). However, NST can produce severe toxicity, so it might not be appropriate for many patients with metastatic RCC. Other novel allogeneic immunotherapies have been designed to induce an autologous immune response directed against the malignancy. This study evaluated the efficacy and safety of infusions of partially HLA-matched irradiated allogeneic blood mononuclear cells for advanced renal-cell carcinoma. Methods: Patients with histologically proven diagnosis of advanced RCC received infusions of partially HLA-matched allogeneic blood mononuclear cells. Repeat infusions were given every 8 weeks. Treatment was continued until disease progressed, unacceptable toxicity, or patient (or donor) choice. Results: Eight patients were enrolled. After every infusion, 6 patients received an oral administration of thalidomide daily with 100-300 mg/d for 2 months. One patient had durable complete response. Five stable diseases and two progress diseases were observed. In eight patients, time to progression and survival were 320 and 879+days, respectively. Severe toxicity was not observed. Conclusion: Infusions of partially HLA-matcbed irradiated allogeneic blood mononuclear cells for advanced RCC may induce some antitumor effects and deserves further study.
